2016

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).

Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W.

(Ann Oncol. 2016 Dec;27(12):2236-2241. doi: 10.1093/annonc/mdw418)

 

Adherence, satisfaction & functional health status among MS patients using the BETACONNECT® auto-injector: results of the BETAEVAL study.

Kleiter I, Lang M, Jeske J, Stollfuss B, Schürks M.

(ECTRIMS Meeting, 09/2016, London, UK)

 

Impact of surgical resection of liver metastases on outcome of patients with KRAS-wildtype exon 2 (KRAS-wt) metastatic colorectal carcinoma (mCRC) treated with a cetuximab-based first-line therapy – Interim analysis of the German noninterventional study ERBITAG.

Neumann U, Goehler T, Hering-Schubert C, Janssen J, Sahm S, Schwittay M, Zahn MO, Stenzel KG, Overkamp F

(Ann Oncol. 2016 Oct 11;27(suppl_6):491P; ESMO Congress 2016, Copenhagen, Denmark)

 

Influence of Circulating Tumour Cells on Production of IL-1α, IL-1β and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment.

Vilsmaier T, Rack B, König A, Friese K, Janni W, Jeschke U, Weissenbacher T; SUCCESS Study Group

(Anticancer Res. 2016 Oct;36(10):5227-5236)

 

CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.

Rack B, Jückstock J, Trapp E, Weissenbacher T, Alunni-Fabbroni M, Schramm A, Widschwendter P, Lato K, Zwingers T, Lorenz R, Tesch H, Schneeweiss A, Fasching P, Mahner S, Beckmann MW, Lichtenegger W, Janni W; SUCCESS Study Group.

(Tumour Biol. 2016 Oct;37(10):13769-13775)

 

Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

Gasch C, Oldopp T, Mauermann O, Gorges TM, Andreas A, Coith C, Müller V, Fehm T, Janni W, Pantel K, Riethdorf S.

(Mol Oncol. 2016 Oct;10(8):1330-43. doi: 10.1016/j.molonc.2016.07.005)

 

Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer – The SUCCESS Trial.

Hepp P, Andergassen U, Jäger B, Trapp E, Alunni-Fabbroni M, Friedl TW, Hecker N, Lorenz R, Fasching P, Schneeweiss A, Fehm T, Janni W, Rack B.

(Anticancer Res. 2016 Sep;36(9):4771-6)

 

Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional ‘QoLiTime’ study.

Hofheinz RD, Lange C, Ecke T, Kloss S, Linsse B, Windemuth-Kieselbach C, Hammerer P, Al-Batran SE.

(BJU Int. 2016 Sep 12. doi: 10.1111/bju.13658. [Epub ahead of print])

 

Expectations and perspectives of ovarian cancer patients about cancer management in Romania. The international NOGGO-ENGOT trial: EXPRESSION III.

Achimaş-Cadariu P, Iancu M, Kubelac P, Pop F, Braicu I, Vlad C, Oskay-Özcelik G, Sehouli J.

(Eur J Cancer Care (Engl). 2016 Aug 10. doi: 10.1111/ecc.12566. [Epub ahead of print])

 

Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial.

Jueckstock J, Rack B, Friedl TW, Scholz C, Steidl J, Trapp E, Tesch H, Forstbauer H, Lorenz R, Rezai M, Häberle L, Alunni-Fabbroni M, Schneeweiss A, Beckmann MW, Lichtenegger W, Fasching PA, Pantel K, Janni W; SUCCESS Study Group.

(BMC Cancer. 2016 Jul 7;16:401. doi: 10.1186/s12885-016-2454-3)

 

Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells.

König A, Vilsmaier T, Rack B, Friese K, Janni W, Jeschke U, Andergassen U, Trapp E, Jückstock J, Jäger B, Alunni-Fabbroni M, Friedl T, Weissenbacher T; SUCCESS STUDY GROUP.

(Anticancer Res. 2016 Jun;36(6):3123-30)

 

Cetuximab in combination with platinum-based chemotherapy or radiotherapy in ecurrent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial).

Hecht M, Hahn D, Beutner D, Reichert D, Göhler T, Wurm R, Welslau M, Renziehausen L, Balermpas P, Bergmann T, Aßmann M, Belka C, Orlowski K, Finzsch M, Illerhaus G, Fietkau R.

(Ann Onol 2016;27:328-350(994P); ESMO Congress 2016, Copenhagen, Denmark)

 

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.

Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T.

(Int J Chron Obstruct Pulmon Dis. 2016 Apr 27;11:891-8. Doi: 10.2147/COPD.S103023)

 

Gute Verträglichkeit des SGLT2-Inhibitors Dapagliflozin bei Patienten mit Typ 1 Diabetes: Vorläufige Ergebnisse einer Phase-1-Studie.

Biester T, Fath M, Gottwald I, Remus K, Aschemeier B, Frey M, Scheerer MF, Kordonouri O, Danne T.

(Diabetologie und Stoffwechsel 2016;11 – P105, Diabetes Kongress, Mai 2016, Berlin)

 

Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.

Schröder L, Rack B, Sommer H, Koch JG, Weissenbacher T, Janni W, Schneeweiss A, Rezai M, Lorenz R, Jäger B, Schramm A, Häberle L, Fasching PA, Friedl TW, Beckmann MW, Scholz C.

(Geburtshilfe Frauenheilkd. 2016 May;76(5):542-550)

 

Expression of Activin During and After Chemotherapy in Peripheral Blood of Patients with Primary Breast Cancer.

Jueckstock J, Burkhardt N, Kuhn C, Blankenstein T, Mahner S, Schindlbeck C, Janni W, Rack B, Mylonas I.

(Anticancer Res. 2016 May;36(5):2153-9)

 

Quality of life (QoL) and therapy management in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI and aflibercept in Germany, Switzerland, and Austria (GSA): Interim results of the noninterventional QoLiTrap-study.

Hofheinz R, Thaler J, Von Moos R.

(J Clin Oncol. 2016;34:4s, abstract 681, ASCO GI Meeting, 2016, San Francisco, USA)

 

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.

Aktas B, Kasimir-Bauer, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M; DETECT Study Group.

(BMC Cancer 2016; 16:522)

 

Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.

Schramm A, Friedl TW, Schochter F, Scholz C, de Gregorio N, Huober J, Rack B, Trapp E, Alunni-Fabbroni M, Müller V, Schneeweiss A, Pantel K, Meier-Stiegen F, Hartkopf A, Taran FA, Wallwiener D, Janni W, Fehm T.

(Arch Gynecol Obstet. 2016 Feb;293(2):271-81. doi: 10.1007/s00404-015-3879-7)

 

Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TRIAS.

Sehouli S, Hilpert F, Mahner S, Neunhoeffer T, Harter P, de Gregorio N, Fridrich C, Markmann S, Richter R, Potenberg J, Lorenz R,  Klare P, Schmidt M, Krabisch P, Groell I,  Doering G, Belau A, Lueck HJ, Du Bois A,  Chekerov R.

(J Clin Oncol 2016; 34 (suppl) abstr 5522)

 

Effect of PSA response on overall and progression-free survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel (Caba): The non-interventional study QoLiTime.

Hammerer P, Al-Batran SE, Windemuth-Kieselbach C, Hofheinz RD.

(Eur Urol Suppl. 2016 Mar;3. Doi: 10.1016/S1569-9056(16)60770-4; EAU Congress 2016, Munich, Germany)

 

Outcome of patients with KRAS exon 2 wildtype (KRAS-wt) metastatic colorectal carcinoma (mCRC) with cetuximab-based first-line treatment in the noninterventional study ERBITAG and impact of comorbidity and age.

Sahm S, Goehler T, Hering-Schubert C, Jannsen J, Neumann UP, Schwittay M, Zahn MO, Stenzel KG, Steinbach-Buechert AK, Overkamp F.

(J Clin Oncol 2016;34(suppl_4):abstract 651; ASCO GI Meeting 2016, San Francisco, USA)

2015

Treosulfan in the Treatment of Advanced Ovarian Cancer – Results of a German Multicenter Non-interventional Study.

Chekerov R, Kaltenecker G, Reichert D, Göhler T, Klare P, Oskay-Özcelik G, Sauer U, Wischnik A, Vehling-Kaiser U, Becker M, Hutzschenreuter U, Ammon A, Heidrich-Lorsbach E, Sehouli J.

(Anticancer Res. 2015 Dec;35(12):6869-75)

 

The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial

Widschwendter P, Friedl TW, Schwentner L, DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K, Weissenbacher T, Kost B, Andergassen U, Jueckstock J, Neugebauer J, Trapp E, Fasching PA, Beckmann MW, Schneeweiss A, Schrader I, Rack B, Janni W, Scholz C.

(Breast Cancer Res. 2015 Sep 18;17:129. doi: 10.1186/s13058-015-0639-3)

 

QoLiTime: Quality-of-Life (QoL) analysis of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel in daily clinical practice.

Hofheinz RD, Al-Batran SE, Windemuth-Kieselbach C, Hammerer P.

(Eur J Cancer. 2015 Sept;51(S3):S499; European Cancer Congress 2015, Vienna; Austria)

 

The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).

Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, Hübner A, Burmester M, Koenigsmann M, Wiegand J, Zur Hausen G, Linsse B, Kuhl R, Pauligk C; Arbeitsgemeinschaft Internistische Onkologie (AIO).

(Ann Oncol. 2015 Jun;26(6):1244-8. Doi: 10.1093/annonc/mdv129)

 

Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study.

Livingstone E, Eigentler TK, Windemuth-Kieselbach C, Hauschild A, Rompel R, Trefzer U, Nashan D, Kilian K, Debus D, Kähler KC, Mauerer A, Möllenhoff K, Dippel E, Schadendorf D. Br J Dermatol.

(2015 Jun;172(6):1646-50. Doi: 10.1111/bjd.13612)

 

Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.

Stückrath I, Rack B, Janni W, Jäger B, Pantel K, Schwarzenbach H.

(Oncotarget. 2015 May 30;6(15):13387-401)

 

The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients.

Fagerholm R, Schmidt MK, Khan S, Rafiq S, Tapper W, Aittomäki K, Greco D, Heikkinen T, Muranen TA, Fasching PA, Janni W, Weinshilboum R, Loehberg CR, Hopper JL, Southey MC, Keeman R, Lindblom A, Margolin S, Mannermaa A, Kataja V, Chenevix-Trench G; kConFab Investigators., Lambrechts D, Wildiers H, Chang-Claude J, Seibold P, Couch FJ, Olson JE, Andrulis IL, Knight JA, García-Closas M, Figueroa J, Hooning MJ, Jager A, Shah M, Perkins BJ, Luben R, Hamann U, Kabisch M, Czene K, Hall P, Easton DF, Pharoah PD, Liu J, Eccles D, Blomqvist C, Nevanlinna H.

(Oncotarget. 2015 Apr 10;6(10):7390-407)

 

Prospective evaluation of follow-up in melanoma patients in Germany – results of a multicentre and longitudinal study.

Livingstone E, Krajewski C, Eigentler TK, Windemuth-Kieselbach C, Benson S, Elsenbruch S, Hauschild A, Rompel R, Meiss F, Mauerer A, Kähler KC, Dippel E, Möllenhoff K, Kilian K, Mohr P, Utikal J, Schadendorf D.

(Eur J Cancer. 2015 Mar;51(5):653-67. Doi: 10.1016/j.ejca.2015.01.007)

 

PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.

Coupe N, Corrie P, Hategan M, Larkin J, Gore M, Gupta A, Wise A, Suter S, Ciria C, Love S, Collins L, Middleton MR.

(Eur J Cancer. 2015 Feb;51(3):359-66. doi: 10.1016/j.ejca.2014.11.018)

 

BETAEVAL- The new BETACONNECT auto-injector: Adherence and EVALuation of MS patients treated with Betaferon: Design and baseline data.

Schürks M, Stollfuss B, Kleiter I.

(Congress of the German Socienty for Neurology, Düsseldorf, Germany)

2014

Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network.

Hohloch K, Lankeit HK, Zinzani PL, Scholz CW, Lorsbach M, Windemuth-Kieselbach C, Trümper L.

(Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1585-92)

 

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.

Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann MW, Friese K, Pantel K, Janni W; SUCCESS Study Group.

(J Natl Cancer Inst. 2014 May 15;106(5). Pii: dju066. Doi: 10.1093/jnci/dju066. Erratum in: J Natl Cancer Inst. 2014 Sep;106(9):doi/10.1093/jnci/dju273)

 

Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer.

Jaeger BA, Jueckstock J, Andergassen U, Salmen J, Schochter F, Fink V, Alunni-Fabbroni M, Rezai M, Beck T, Beckmann MW, Friese K, Friedl TW, Janni W, Rack B.

(Biomed Res Int. 2014;2014:491459. Doi: 10.1155/2014/491459)

 

Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.

Rom J, Bechstein S, Domschke C, Golatta M, Mayer C, Heil J, Thum J, Smetanay K, Windemuth-Kieselbach C, Wallwiener M, Marme F, Schuetz F, Sohn C, Schneeweiss A.

(Anticancer Drugs. 2014 Feb;25(2):219-24. Doi: 10.1097/CAD.0000000000000037)

 

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.

Hadji P, Jackisch C, Bolten W, Blettner M, Hindenburg HJ, Klein P, König K, Kreienberg R, Rief W, Wallwiener D, Zaun S, Harbeck N.

(Ann Oncol. 2014 Feb;25(2):372-7)

 

The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (The QoLiTax-Trial of the Arbeitsgemeinschaft

Internistische Onkologie, AIO)

Pauligk C, Hozaeel W, Hofheinz R, Hinke A, Windemuth-Kieselbach C, Tauchert FK et al.

(J Clin Oncol. 2014;32:5s, abstract 9621, ASCO Meeting 2014, Chicago, USA)

2013

Drehscheibe der klinischen Prüfung – die Rolle der Clinical Research Organization.

Heidrich-Lorsbach E, Härtlein H.

(Onkologische Pharmazie 2013;15(2):24-27)

 

The Patient’s Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer.

Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Kreienberg R.

(Ann Oncol. 2013 Jun;24(6):1505-12. Doi: 10.1093/annonc/mds653)

 

Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer.

Andergassen U, Kasprowicz NS, Hepp P, Schindlbeck C, Harbeck N, Kiechle M, Sommer H, Beckmann MW, Friese K, Janni W, Rack B, Scholz C; for the SUCCESS study group.

(Geburtshilfe Frauenheilkd. 2013 Jan;73(1):63-69)

2012

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study

Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T; DETECT study group.

(Breast Cancer Res. 2012 Aug 15;14(4):R118. Doi: 10.1186/bcr3243)

 

A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis.

Mahner S, Oskay-Özcelik G, Heidrich-Lorsbach E, Fuxius S, Sommer H, Klare P, Belau A, Ruhmland B, Heuser T, Kölbl H, Markmann S, Sehouli J.

(J Cancer Res Clin Oncol. 2012 Aug;138(8):1413-9. Doi: 10.1007/s00432-012-1221-3)

 

Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.

Schwarzenbach H, Eichelser C, Kropidlowski J, Janni W, Rack B, Pantel K.

(Clin Cancer Res. 2012 Oct 15;18(20):5719-30. Doi: 10.1158/1078-0432.CCR-12-0142)

2011

The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.

Eichbaum M, Mayer C, Eickhoff R, Bischofs E, Gebauer G, Fehm T, Lenz F, Fricke HC, Solomayer E, Fersis N, Schmidt M, Wallwiener M, Schneeweiss A, Sohn C.

(BMC Cancer. 2011 Oct 20;11:453. Doi: 10.1186/1471-2407-11-453)

 

Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network.

Hohloch K, Delaloye AB, Windemuth-Kieselbach C, Gómez-Codina J, Linkesch W, Jurczak W, Cacchione R, Suh C, Zinzani PL, Trümper L.

(J Nucl Med. 2011 Sep;52(9):1354-60. Doi: 10.2967/jnumed.111.089920)

 

A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up.

Livingstone E, Windemuth-Kieselbach C, Eigentler TK, Rompel R, Trefzer U, Nashan D, Rotterdam S, Ugurel S, Schadendorf D.

(Eur J Cancer. 2011 Sep;47(13):1977-89. Doi: 10.1016/j.ejca.2011.04.029)

 

Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.

Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, Rack B, Schneeweiss A, Fehm T.

(2011 Aug;122(2):356-60. Doi: 10.1016/j.ygyno.2011.04.039)

 

Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group.

Pietzner K, Richter R, Chekerov R, Erol E, Oskay-Özcelik G, Lichtenegger W, Sehouli J.

(Anticancer Res. 2011 Aug;31(8):2679-82)

 

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.

Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Zeitz J, Pantel K, Fehm T; DETECT study group.

(Breast Cancer Res. 2011 Jul 11;13(4):R71. Doi: 10.1186/bcr2916)

 

Treatment of malignant sinonasal tumours with intensity-modulated radiotherapy (IMRT) and carbon ion boost (C12).

Jensen AD, Nikoghosyan AV, Windemuth-Kieselbach C, Debus J, Münter MW.

(BMC Cancer. 2011 May 22;11:190. Doi: 10.1186/1471-2407-11-190)

 

Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx – TPF-C-HIT.

Jensen AD, Krauss J, Potthoff K, Desta A, Habl G, Mavtratzas A, Windemuth-Kiesselbach C, Debus J, Münter MW.

(BMC Cancer. 2011; 11: 182. Published online 2011 May 19. doi: 10.1186/1471-2407-11-182)

 

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G.

(J Clin Oncol. 2011 Jan 10;29(2):242-8. Doi: 10.1200/JCO.2009.27.8911)

2010

Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment.

Rack B, Schindlbeck C, Jückstock J, Genss EM, Hepp P, Lorenz R, Tesch H, Schneeweiss A, Beckmann MW, Lichtenegger W, Sommer H, Friese K, Janni W; SUCCESS Study Group.

(Anticancer Res. 2010 May;30(5):1837-41)

 

The German SUCCESS C Study – The First European Lifestyle Study on Breast Cancer.

Rack B, Andergassen U, Neugebauer J, Salmen J, Hepp P, Sommer H, Lichtenegger W, Friese K, Beckmann MW, Hauner D, Hauner H, Janni W.

(Breast Care (Basel). 2010;5(6):395-400)

 

Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.

Oskay-Ozcelik G, Chekerov R, Sommer H, Keil E, Einenkel J, Pfisterer J, Lorenz-Schlüter C, Lichtenegger W, Camara O, Sehouli J.

(Gynecol Oncol. 2010 Mar;116(3):317-22. doi: 10.1016/j.ygyno.2009.09.031)

 

Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC.

Jensen AD, Nikoghosyan A, Windemuth-Kieselbach C, Debus J, Münter MW.

(BMC Cancer. 2010 Oct 11;10:546. Doi: 10.1186/1471-2407-10-546)

 

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K.

(Breast Cancer Res Treat. 2010 Nov;124(2):403-12. doi: 10.1007/s10549-010-1163-x)